Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Effects of TCF7L2 rs7903146 variant on metformin response in patients with type 2 diabetes

Dujic, Tanja ; Bego, Tamer ; Malenica, Maja ; Velija-Asimi, Zelija ; Ahlqvist, Emma LU ; Groop, Leif LU ; Pearson, Ewan R. LU ; Causevic, Adlija and Semiz, Sabina (2019) In Bosnian Journal of Basic Medical Sciences 19(4). p.368-374
Abstract

The response to metformin, the most commonly used drug for the treatment of type 2 diabetes (T2D), is highly variable. The common variant rs7903146 C>T within the transcription factor 7-like 2 gene (TCF7L2) is the strongest genetic risk factor associated with T2D to date. In this study, we explored the effects of the TCF7L2 rs7903146 genotype on metformin response in T2D. The study included 86 newly diagnosed patients with T2D, incident users of metformin. Levels of fasting glucose, insulin, HbA1c, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, and anthropometric parameters were measured prior to metformin therapy, and 6 and 12 months after the treatment. Genotyping of the TCF7L2 rs7903146 was... (More)

The response to metformin, the most commonly used drug for the treatment of type 2 diabetes (T2D), is highly variable. The common variant rs7903146 C>T within the transcription factor 7-like 2 gene (TCF7L2) is the strongest genetic risk factor associated with T2D to date. In this study, we explored the effects of the TCF7L2 rs7903146 genotype on metformin response in T2D. The study included 86 newly diagnosed patients with T2D, incident users of metformin. Levels of fasting glucose, insulin, HbA1c, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, and anthropometric parameters were measured prior to metformin therapy, and 6 and 12 months after the treatment. Genotyping of the TCF7L2 rs7903146 was performed by the Sequenom MassARRAY® iPLEX® platform. At baseline, the diabetes risk allele (T) showed an association with lower triglyceride levels (p = 0.037). After 12 months of metformin treatment, the T allele was associated with 25.9% lower fasting insulin levels (95% CI 10.9-38.3%, p = 0.002) and 29.1% lower HOMA-IR index (95% CI 10.1-44.1%, p = 0.005), after adjustment for baseline values. Moreover, the T allele was associated with 6.7% lower fasting glucose levels (95% CI 1.1-12.0%, p = 0.021), adjusted for baseline glucose and baseline HOMA-%B levels, after 6 months of metformin treatment. This effect was more pronounced in the TT carriers who had 16.8% lower fasting glucose levels (95% CI 7.0-25.6%, p = 0.002) compared to the patients with CC genotype. Our results suggest that the TCF7L2 rs7903146 variant affects markers of insulin resistance and glycemic response to metformin in newly diagnosed patients with T2D within the first year of metformin treatment.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Metformin, Pharmacogenetics, TCF7L2, Transcription factor 7-like 2 gene, Type 2 diabetes
in
Bosnian Journal of Basic Medical Sciences
volume
19
issue
4
pages
368 - 374
publisher
Association of Basic Medical Sciences Federation of Bosnia and Herzegovina
external identifiers
  • scopus:85074743887
  • pmid:31070566
ISSN
1512-8601
DOI
10.17305/bjbms.2019.4181
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2019, Association of Basic Medical Sciences of FBIH. All rights reserved.
id
b28cbe74-33ca-4ab5-9891-09e6bb4ba438
date added to LUP
2021-12-21 12:50:01
date last changed
2024-04-20 18:12:57
@article{b28cbe74-33ca-4ab5-9891-09e6bb4ba438,
  abstract     = {{<p>The response to metformin, the most commonly used drug for the treatment of type 2 diabetes (T2D), is highly variable. The common variant rs7903146 C&gt;T within the transcription factor 7-like 2 gene (TCF7L2) is the strongest genetic risk factor associated with T2D to date. In this study, we explored the effects of the TCF7L2 rs7903146 genotype on metformin response in T2D. The study included 86 newly diagnosed patients with T2D, incident users of metformin. Levels of fasting glucose, insulin, HbA<sub>1c</sub>, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, and anthropometric parameters were measured prior to metformin therapy, and 6 and 12 months after the treatment. Genotyping of the TCF7L2 rs7903146 was performed by the Sequenom MassARRAY® iPLEX® platform. At baseline, the diabetes risk allele (T) showed an association with lower triglyceride levels (p = 0.037). After 12 months of metformin treatment, the T allele was associated with 25.9% lower fasting insulin levels (95% CI 10.9-38.3%, p = 0.002) and 29.1% lower HOMA-IR index (95% CI 10.1-44.1%, p = 0.005), after adjustment for baseline values. Moreover, the T allele was associated with 6.7% lower fasting glucose levels (95% CI 1.1-12.0%, p = 0.021), adjusted for baseline glucose and baseline HOMA-%B levels, after 6 months of metformin treatment. This effect was more pronounced in the TT carriers who had 16.8% lower fasting glucose levels (95% CI 7.0-25.6%, p = 0.002) compared to the patients with CC genotype. Our results suggest that the TCF7L2 rs7903146 variant affects markers of insulin resistance and glycemic response to metformin in newly diagnosed patients with T2D within the first year of metformin treatment.</p>}},
  author       = {{Dujic, Tanja and Bego, Tamer and Malenica, Maja and Velija-Asimi, Zelija and Ahlqvist, Emma and Groop, Leif and Pearson, Ewan R. and Causevic, Adlija and Semiz, Sabina}},
  issn         = {{1512-8601}},
  keywords     = {{Metformin; Pharmacogenetics; TCF7L2; Transcription factor 7-like 2 gene; Type 2 diabetes}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{368--374}},
  publisher    = {{Association of Basic Medical Sciences Federation of Bosnia and Herzegovina}},
  series       = {{Bosnian Journal of Basic Medical Sciences}},
  title        = {{Effects of TCF7L2 rs7903146 variant on metformin response in patients with type 2 diabetes}},
  url          = {{http://dx.doi.org/10.17305/bjbms.2019.4181}},
  doi          = {{10.17305/bjbms.2019.4181}},
  volume       = {{19}},
  year         = {{2019}},
}